Investment Analysts’ Weekly Ratings Updates for IO Biotech (IOBT)

Several brokerages have updated their recommendations and price targets on shares of IO Biotech (NASDAQ: IOBT) in the last few weeks:

• 1/10/2026 – IO Biotech was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 1/8/2026 – IO Biotech was downgraded by analysts at Morgan Stanley from an “equal weight” rating to an “underweight” rating.
• 12/29/2025 – IO Biotech had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/29/2025 – IO Biotech was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/22/2025 – IO Biotech had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/21/2025 – IO Biotech was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 12/15/2025 – IO Biotech had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/13/2025 – IO Biotech was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/8/2025 – IO Biotech had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – IO Biotech had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – IO Biotech had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/23/2025 – IO Biotech was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/17/2025 – IO Biotech had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.

IO Biotech ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors.

Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma.